UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
Current Report
Pursuant To Section 13 or 15 (d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) - July 29, 2009
 
 
NUCRYST PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its charter)
 
Alberta, Canada
 
000-51686
 
Not Applicable
(State or other jurisdiction of
incorporation or organization)
 
(Commission File Number)
 
(I.R.S. Employer Identification No.)
NUCRYST Pharmaceuticals Corp.
101 College Road East
Princeton, New Jersey 08540
 
(Address of principal executive offices)
 
Registrant’s telephone number, including area code: (609) 228-8210
 
Not applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

o       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
(Former name or former address, if changed since last report)
 
 
 
 
 
 
 
 
Item 8.01
Other Events.
 
On July 29, 2009 NUCRYST Pharmaceuticals Corp. (“NUCRYST”), a developer and manufacturer of medical products that fight infection and the Advanced Wound Management division of Smith & Nephew plc announced that the US Food & Drug Administration (FDA) has granted the 510(k) marketing clearance for Acticoat™ Flex, an antimicrobial barrier dressing designed to conform to body contours and allows for flexible movement for injuries that require sustained antimicrobial activity.  Acticoat™ Flex is a new addition to the Acticoat™ family and is coated with NUCRYST’s patented SILCRYST™ nanocrystalline silver technology.
 
Item 9.01
Financial Statements and Exhibits

(d) Exhibits.

Exhibit
Number
Description
 
99.1
Press Release dated July 29, 2009, titled “New ACTICOAT™ Silver Coated Anti-microbial Barrier Dressing Receives 510(k) Clearance from US FDA”
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  Nucryst Pharmaceuticals Corp.  
       
 
By:
/s/ Carol L. Amelio  
    Carol L. Amelio  
   
Vice President, General Counsel and Corporate Secretary
 
Dated: July 29, 2009
     

 
 
 
 
 
EXHIBIT INDEX
 
Exhibit
Number
Description
 
99.1
Press Release dated July 29, 2009, titled “New ACTICOAT™ Silver Coated Anti-microbial Barrier Dressing Receives 510(k) Clearance from US FDA”

Nucryst (NASDAQ:NCST)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Nucryst Charts.
Nucryst (NASDAQ:NCST)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Nucryst Charts.